NYSE:MBX MBX Biosciences (MBX) Stock Price, News & Analysis $8.70 +0.07 (+0.81%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$8.70 0.00 (-0.06%) As of 03/14/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About MBX Biosciences Stock (NYSE:MBX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MBX Biosciences alerts:Sign Up Key Stats Today's Range$8.58▼$9.4850-Day Range$8.63▼$16.2852-Week Range$8.54▼$27.50Volume159,770 shsAverage Volume224,523 shsMarket Capitalization$290.73 millionP/E RatioN/ADividend YieldN/APrice Target$37.25Consensus RatingBuy Company OverviewMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Read More… Remove Ads MBX Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreMBX MarketRank™: MBX Biosciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 811th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMBX Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMBX Biosciences has received no research coverage in the past 90 days.Read more about MBX Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MBX Biosciences are expected to grow in the coming year, from ($13.25) to ($2.30) per share. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MBX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMBX Biosciences does not currently pay a dividend.Dividend GrowthMBX Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MBX. News and Social Media0.8 / 5News SentimentN/A News SentimentMBX Biosciences has a news sentiment score of -0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MBX Biosciences this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, MBX Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,555,308.00 in company stock and sold $0.00 in company stock.Read more about MBX Biosciences' insider trading history. Receive MBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MBX Stock News HeadlinesInsider Buyers At MBX Biosciences Likely Disappointed With 17% SlideMarch 13 at 7:52 PM | finance.yahoo.comMBX Biosciences, Inc.'s (NYSE:MBX) Lock-Up Period Set To Expire on March 12thMarch 7, 2025 | americanbankingnews.comLying in hospital… staring at the light"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 15, 2025 | Porter & Company (Ad)MBX Biosciences announces additions to its leadership teamMarch 6, 2025 | markets.businessinsider.comMBX Biosciences Announces Additions to Leadership TeamMarch 5, 2025 | globenewswire.comMBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109March 3, 2025 | markets.businessinsider.comMBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for HypoparathyroidismMarch 3, 2025 | globenewswire.comOrbiMed Advisors makes $2 million investment in MBX BiosciencesFebruary 22, 2025 | investing.comSee More Headlines MBX Stock Analysis - Frequently Asked Questions How have MBX shares performed this year? MBX Biosciences' stock was trading at $18.43 at the beginning of the year. Since then, MBX stock has decreased by 52.8% and is now trading at $8.70. View the best growth stocks for 2025 here. How were MBX Biosciences' earnings last quarter? MBX Biosciences, Inc. (NYSE:MBX) posted its earnings results on Thursday, November, 7th. The company reported ($2.78) EPS for the quarter, missing analysts' consensus estimates of ($2.72) by $0.06. When did MBX Biosciences IPO? MBX Biosciences (MBX) raised $163 million in an IPO on Friday, September 13th 2024. The company issued 10,200,000 shares at $16.00 per share. When did MBX Biosciences' lock-up period expire? MBX Biosciences' lock-up period expired on Wednesday, March 12th. MBX Biosciences had issued 10,200,000 shares in its initial public offering on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period. Who are MBX Biosciences' major shareholders? Top institutional investors of MBX Biosciences include Wellington Management Group LLP (8.71%), Driehaus Capital Management LLC (4.73%), Price T Rowe Associates Inc. MD (3.48%) and Woodline Partners LP (1.82%). Insiders that own company stock include Life Sciences X LP Frazier, Edward T Mathers and P Kent Hawryluk. View institutional ownership trends. How do I buy shares of MBX Biosciences? Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MBX Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN). Company Calendar Last Earnings11/07/2024Today3/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:MBX Previous SymbolNYSE:MBX CIK1776111 Webmbxbio.com Phone(317) 659-0200FaxN/AEmployees36Year FoundedN/APrice Target and Rating Average Stock Price Target$37.25 High Stock Price Target$44.00 Low Stock Price Target$30.00 Potential Upside/Downside+328.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares33,417,000Free FloatN/AMarket Cap$290.73 million OptionableN/A BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NYSE:MBX) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.